Trial · NCT06967155
A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer
NCT06967155, Phase 2, Active not recruiting, Blokhin's Russian Cancer Research Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer. Trials, record NCT06967155. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06967155
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer
- NCT number
- NCT06967155
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 23 participants, estimated
- Lead sponsor
- Blokhin's Russian Cancer Research Center
- Conditions
- Neoplasms
- Interventions
- • Drug: Dabrafenib • Drug: Trametinib • Drug: Cetuximab • Drug: Рanitumumab • Drug: Oxaliplatin • Drug: Irinotecan • Drug: Leucovorin • Drug: 5-FU
- First posted
- 2025-05-13
- Last updated
- 2025-10-02
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate | assessed up to 12 months | From date of enrollment until the date of first documented progression |
| Secondary | Progression-free survival | assessed up to 24 months | From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first |
| Secondary | Time to objective response | assessed up to 6 months | Time from start of treatment to objective response to treatment |
| Secondary | Duration of response | assessed up to 12 months | Calculated from achieving objective response to progression or death from any cause |
| Secondary | Disease control rate | Percentage of patients who achieved a complete response, partial response or disease stabilisation? through study completion, an average of 1 year | |
| Secondary | Overall survival | assessed up to 36 months | From the time of enrolment until the death from any cause |
| Secondary | Incidence of adverse events | Proportion of patients with adverse events out of all patients (NCI CTCAE 5.0) | |
| Secondary | Incidence of adverse events grade 3-4 | Proportion of patients with adverse events grade 3-4 out of all patients (NCI CTCAE 5.0) | |
| Secondary | Reduction of dose reductions and drug withdrawals | Proportion of patients with dose reductions and drug withdrawals in the total number of patients |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06967155
GET https://conductscience.org/api/trials/v1/NCT06967155/registered